Table 2 Utility values and costing data considered in the model
From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
Parameters | Values | Source |
|---|---|---|
Utility values | ||
No hospitalization | SHIFT trial | |
NYHA I | 0.82 | |
NYHA II | 0.74 | |
NYHA III | 0.64 | |
NYHA IV | 0.46 | |
Hospitalization | SHIFT trial | |
NYHA I | −0.04 | |
NYHA II | −0.07 | |
NYHA III | −0.10 | |
NYHA IV | −0.29 | |
Drug costs per month | price bulletin issued by the Greek Ministry of Health [15], law 4052/2012, Government Gazette | |
Standard care | €35.26 | |
Ivabradine | €40.52 | |
Other therapy related costs | ||
ECG | €3.44 | |
Hospitalization cost (cost per diem) | Government Gazzette, Ministerial Desicion 104494, 26/9/2011 | |
Intensive Care Unit | €200 | |
Cardiac Units | €110 | |
Other resource use | Government Gazzette [16] and local experts’ opinion | |
On-going HF management costs | €26.05 |